Inhibition of Ganglioside Biosynthesis by Imino Sugars Reduces Binding of

Guillain-Barré Syndrome Autoantibodies.

Rhea McGarryGlycobiology Department

Oxford UniversityTrinity College

Introduction

• Autoimmune DiseaseThe immune system must be able to discriminate

between self- and non-self antigens, in order to prevent self destruction. This is termed self-tolerance, the loss of which results in autoimmune disease.

Antibody mediated autoimmune disease, such as GBS, are driven by a loss of tolerance in both the B and T lymphocytes, as a consequence of molecular mimicry between self and non-self lipo-oligosaccharides (LOS).

Molecular mimicry and autoimmunity

The adaptive immune response which continuously monitors for infection may generate a response against an epitope that is very similar, both to the microbe and the host.

This results in an attack on the host tissue by the same mechanism which has been activated to eliminate the pathogen.

In this case, molecular mimicry is occurring as the epitope is an intrinsic part of the body and so constant synthesis of antigen prevents clearance and consequently sustained B cell activation and antibody production.

GBS and C. jejuni

• Some form of infection was found to precede nearly 90% of GBS Some form of infection was found to precede nearly 90% of GBS cases (Koga et al., 2001). The gram-negative bacteria cases (Koga et al., 2001). The gram-negative bacteria Campylobacter jejuni Campylobacter jejuni is a leading cause of acute gastroenteritis in is a leading cause of acute gastroenteritis in developed countries developed countries The mimicry is occurring between C. jejuni lipo-oligosaccharides and peripheral nerve gangliosides.

• The most frequent anti-Ganglioside antibodies were of the class IgG, against GM1, GM1b, GD1a and GalNAc-GD1a (Willison et al., 2002). Antibodies reactive to GM3 and GD1b have also been identified (Usuki et al., 2006).

Core-lipid A Ceramide

Bacterial GM1-like LOS

Human GM1

GBS pathology and treatment

Guillian-Barré syndrome is characterised by symmetrical limb weakness and loss of tendon flexes and has 3 subtypes.

GBS is a self-limiting disease which occurs 1-3 weeks after infection. Muscle weakness can reach nadir within 4 weeks, followed by partial or complete recovery over weeks to months.

Therapies include plasma exchange and high-dose intravenous IgG. The therapeutic effect of plasma exchange is related to the removal or dilution of circulating factors. Therapy is often not effective.

Treatments do have side effects, including skin rashes and transient liver disturbances and the efficiency of both methods are limited.

Imino sugars as inhibitors

An alternative method, which was developed in my study, involves metabolically reducing the level of auto-epitopes.

This is done by inhibiting the glycosphingolipid (GSL) biosynthetic pathway using imino sugars which inhibit the enzyme ceramide-specific glucosyltransferase (CSGT).

Butters et al, 2000, Chemical Reviews, V100, 12, p4683-4696

Study aim

The aim of my study was to show the therapeutic potential of NB-DNJ and NB-DGJ and NP-IDJ as drugs for Guillain-Barré syndrome through reduction of the levels of ganglioside auto-epitopes present in the cell.

GBS sera binding to RAW cells

healthy GBS+ve

GBS sera binding to RAW cells can be reduced by NB-DNJ

GBS+veGBS+ve

+ NB-DNJ (1mM)

GBS sera binding to RAW cells can be reduced by NB-DNJ

0

10

20

30

40

50

60

0.01 0.1 1 10 100 1000

[NB-DNJ]

Mea

n F

luo

resc

ence

(F

ITC

)

GBS

Geo Mean H

Can the binding be explained by GM1 depletion

Method:

Extract GSLs from cells (+/- NB-DNJ)

Remove carbohydrate with ceramide glycanase

Label reducing terminus with 2-AA

Run labelled sugars on RP-HPLC and measure retention time.

Inhibition of GM1 antigen by NB-DNJ

200μM

100μM

50μM

25μM

5μM

0μM

NB-DNJ

GD1aGM1a

GD1aGM1a

50% reduction in GM1 at 5M NB-DNJ

Application of method to a range of clinical samples

• 10 samples with GBS-like symptoms.. From John Radcliffe Hospital

• ELISA plates coated with GM1• Probed with serial dilution of sera from patients• Detected with anti-human-HRP

0

0.2

0.4

0.6

0.8

1

1.2

1.4

0.0001 0.001 0.01 0.1

Serum Dilution

p1

p2

p3

p4

p5

p6

p7

p8

p9

p10

hc

bl

Some, but not all “GBS” sera show reactivity to GM1 by ELISA

But…

GBS+ve Pat6GBS-ve Healthy control

Summary/explanation for inconsistent results

• Why might some patient sera with similar antigenic profiles (by ELISA) react differently to cell surface?

• GM1 not presented at the cell surface, as is on ELISA plate. Complex and clustering may be inhibiting binding of antibodies.

• Some patient sera more sensitive to effects of this than others.

• Future experiments to resolve this..

Would need fairly high doses of NB-DNJ (>10uM) to achieve >50%

reduction in antigen

• So, may need to try other drugs for actual therapy.. Hence compared to NB-DGJ and NP-IDJ

N

HO OH

CH2OH

HO

(CH2)4CH3

N-pentyl-idonojirimycin

NB-DGJ

GM2GD2

GM2 GD2

NP-IDJ

GM2

GM2

GD2

GD2

32.00

SATIN - Fluorescencem

V

50.00

350.00

SATIN - Fluorescence

mV

100.00

200.00

300.00

SATIN - Fluorescence

mV

200.00

400.00

SATIN - Fluorescence

mV

200.00

400.00

SATIN - Fluorescence

mV

200.00

400.00

SATIN - Fluorescence

mV

200.00

400.00

Minutes

10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.0032.00

SATIN - Fluorescencem

V

50.00

350.00

SATIN - Fluorescence

mV

100.00

200.00

300.00

SATIN - Fluorescence

mV

200.00

400.00

SATIN - Fluorescence

mV

200.00

400.00

SATIN - Fluorescence

mV

200.00

400.00

SATIN - Fluorescence

mV

200.00

400.00

Minutes

10.00 12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00

NB-DNJ

GD2

GD2

GM2

GM2

0

20

40

60

80

100

120

NB-DNJ NB-DGJ NP-IDJ

Reduction in gangliosides with: NB-DNJ, NB-DGJ, NP-IDJ

0µM 200µM 200µM 200µM0µM 0µM

Summary

I was able to show using GSL analysis, that the concentration of gangliosides and neutral glycolipids were reduced on introduction of imino sugar drugs.

I was unable to replicate initial observations with patient 8, with the new patient sera, showing the reduction in binding at the cell surface due to reduced ganglioside synthesis, caused by the introduction of the drug. Further experiments are needed to distinguish between GM1-reactive sera types.